Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Aprotinin
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
Year introduced: 1990
aprotinin, desprolyl(2)-arginyl(15)- [Supplementary Concept]
a plasma kallikrein inhibitor
Date introduced: April 20, 1995
aprotinin, desprolyl(2)-valyl(15)-leucyl(17)- [Supplementary Concept]
extracted from the culture broth of a recombinant Saccharomyces cerevisiae
Date introduced: March 2, 1994
technetium Tc 99m aprotinin [Supplementary Concept]
used in kidney scanning
Date introduced: July 5, 1984
aprotinin, Arg(15)-Glu(52)- [Supplementary Concept]
base sequence of recombinat form given in first source
Date introduced: January 5, 1989
trasylol, Arg(15)- [Supplementary Concept]
Date introduced: November 6, 1984
ATPase inhibitory protein, aprotinin [Supplementary Concept]
found in commercial aprotinin prep; a potent inhibitory protein of chloroplast or mitochondrial ATPase
Date introduced: April 21, 1980
Gabexate
A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Year introduced: 1992
Fibrin Tissue Adhesive
An autologous or commercial tissue adhesive containing FIBRINOGEN and THROMBIN. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, FACTOR VIII, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agents such as APROTININ. Mixing of the two components promotes BLOOD CLOTTING and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, HEMOSTASIS, and WOUND HEALING.
Trypsin Inhibitor, Kazal Pancreatic
A secreted KAZAL MOTIF-containing serine peptidase inhibitor that inhibits TRYPSIN. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ). It protects against the trypsin-mediated premature activation of ENZYME PRECURSORS in the PANCREAS. Mutations in the SPINK1 gene are associated with CHRONIC PANCREATITIS.
Year introduced: 1991(1975)
tachocomb [Supplementary Concept]
a hemostyptic agent; composed of fibrinogen, thrombin and aprotinin integrated into the surface of a collagen fleece
Date introduced: July 7, 1995
(homoserine lactone-52)-52,53-seco-BPTI [Supplementary Concept]
a cyanogen bromide-cleaved bovine basic pancreatic trypsin inhibitor with a homoserine lactone at position 52
Date introduced: January 6, 1995
recombinant neutrophil elastase inhibitor R-020 [Supplementary Concept]
codes the second domain of human urinary trypsin inhibitor (UTI); resembles aprotinin; amino acid sequence given in first source
Date introduced: December 30, 1994
tetrapeptide carbamate [Supplementary Concept]
the combination of aprotinin with leucocyte elastase inhibitor PC5 prevents ulceration of the cornea & inhibits corneal vascularization after soft contact lens wear
Date introduced: July 29, 1992
oviductin [Supplementary Concept]
N-terminal amino acid sequence given in first source; processes Xenopus laevis envelope glycoprotein gp43 by cleaving an arginyl-X bond; inhibited by diisopropyl fluorophosphate, EDTA, EGTA, soybean trypsin inhibitor, aprotinin and guanidine HCl; MW 66,000
Date introduced: June 17, 1992
chymotrypsinogen A activating enzyme [Supplementary Concept]
rat submaxillary enzyme activates chymotrypsinogen A; inhibited by soybean trypsin inhibitor, aprotinin and benzamidine
Date introduced: May 26, 1992
aminopeptidase K [Supplementary Concept]
removes Ala(16) and Arg(17) sequentially from aprotinin which has been cleaved between Lys(15) and Ala(16)
Date introduced: October 16, 1991
Eupergit-aprotinin [Supplementary Concept]
carrier for purification of serine proteases
Date introduced: October 24, 1990
spleen protease inhibitor II [Supplementary Concept]
differs from aprotinin by seven amino acids; has been sequenced
Date introduced: March 1, 1990
gordox [Supplementary Concept]
Drugs having as their active substance aprotinin (trasylol, gordox); gordox and contrycal are distinct molecules that both act as kallikrenin protease inhibitors
Date introduced: January 1, 1976